While so far there are no FDA approved TLR4 antagonists available, intensive research [106] on TLR4 as a therapeutic target is ongoing, with emphasis on respiratory and neurological complications of SARS-CoV-2 [107], also with respect to accumulating data for long-term nervous system consequences after COVID-19 [108,109]. Here, TLR4 is linked to COVID-19.